Advanced glycation end products contribute to the immunogenicity of IFN-[beta] pharmaceuticals

Protein-derived AGEs are formed in both eukaryotic and prokaryotic cells. [...]we hypothesized that human IFN-β produced in either Chinese hamster ovary cells (IFN-β1a) or E coli (IFN-β1b) will accumulate AGEs. [...]experimental data support involvement of both innate6 and adaptive7 immune reacti...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2012-03, Vol.129 (3), p.855
Main Authors: Bozhinov, Angelina, Handzhiyski, Yordan, Genov, Krasimir, Daskalovska, Vera, Niwa, Toshimitsu, Ivan ov, Ivan, Mironova, Roumyana
Format: Article
Language:English
Subjects:
Age
E coli
Multiple sclerosis
Patients
Pharmaceuticals
Proteins
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page 855
container_title Journal of allergy and clinical immunology
container_volume 129
creator Bozhinov, Angelina
Handzhiyski, Yordan
Genov, Krasimir
Daskalovska, Vera
Niwa, Toshimitsu
Ivan ov, Ivan
Mironova, Roumyana
description Protein-derived AGEs are formed in both eukaryotic and prokaryotic cells. [...]we hypothesized that human IFN-β produced in either Chinese hamster ovary cells (IFN-β1a) or E coli (IFN-β1b) will accumulate AGEs. [...]experimental data support involvement of both innate6 and adaptive7 immune reactions against AGEs.
doi_str_mv 10.1016/j.jaci.2011.10.035
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1504825689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3239424511</sourcerecordid><originalsourceid>FETCH-proquest_journals_15048256893</originalsourceid><addsrcrecordid>eNqNjr1uwjAUha2qSE2hL9DpSsxJrwkJ8VghULt06oYAGecCjohN42sk3r4e-gCdPp0fHR0hXiUWEmX91hWdNraYoZTJKLCsHkQmUS3yuplVjyJDVDKvF3P1JJ5D6DDpslGZ2L23N-0MtXC63I1m6x2Qa-E6-DYaDmC848EeIhOwBz4T2L6Pzp_IWWP5Dv4In-uvfHMg1lu4nvXQa0ORrdGXMBGjYwK9_HEspuvV9_IjT_s_kQLvOx8Hl6K9rHCevtaNKv_X-gWJHkw4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504825689</pqid></control><display><type>article</type><title>Advanced glycation end products contribute to the immunogenicity of IFN-[beta] pharmaceuticals</title><source>Elsevier</source><creator>Bozhinov, Angelina ; Handzhiyski, Yordan ; Genov, Krasimir ; Daskalovska, Vera ; Niwa, Toshimitsu ; Ivan ov, Ivan ; Mironova, Roumyana</creator><creatorcontrib>Bozhinov, Angelina ; Handzhiyski, Yordan ; Genov, Krasimir ; Daskalovska, Vera ; Niwa, Toshimitsu ; Ivan ov, Ivan ; Mironova, Roumyana</creatorcontrib><description>Protein-derived AGEs are formed in both eukaryotic and prokaryotic cells. [...]we hypothesized that human IFN-β produced in either Chinese hamster ovary cells (IFN-β1a) or E coli (IFN-β1b) will accumulate AGEs. [...]experimental data support involvement of both innate6 and adaptive7 immune reactions against AGEs.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2011.10.035</identifier><language>eng</language><publisher>St. Louis: Elsevier Limited</publisher><subject>Age ; E coli ; Multiple sclerosis ; Patients ; Pharmaceuticals ; Proteins</subject><ispartof>Journal of allergy and clinical immunology, 2012-03, Vol.129 (3), p.855</ispartof><rights>Copyright Elsevier Limited Mar 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Bozhinov, Angelina</creatorcontrib><creatorcontrib>Handzhiyski, Yordan</creatorcontrib><creatorcontrib>Genov, Krasimir</creatorcontrib><creatorcontrib>Daskalovska, Vera</creatorcontrib><creatorcontrib>Niwa, Toshimitsu</creatorcontrib><creatorcontrib>Ivan ov, Ivan</creatorcontrib><creatorcontrib>Mironova, Roumyana</creatorcontrib><title>Advanced glycation end products contribute to the immunogenicity of IFN-[beta] pharmaceuticals</title><title>Journal of allergy and clinical immunology</title><description>Protein-derived AGEs are formed in both eukaryotic and prokaryotic cells. [...]we hypothesized that human IFN-β produced in either Chinese hamster ovary cells (IFN-β1a) or E coli (IFN-β1b) will accumulate AGEs. [...]experimental data support involvement of both innate6 and adaptive7 immune reactions against AGEs.</description><subject>Age</subject><subject>E coli</subject><subject>Multiple sclerosis</subject><subject>Patients</subject><subject>Pharmaceuticals</subject><subject>Proteins</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNjr1uwjAUha2qSE2hL9DpSsxJrwkJ8VghULt06oYAGecCjohN42sk3r4e-gCdPp0fHR0hXiUWEmX91hWdNraYoZTJKLCsHkQmUS3yuplVjyJDVDKvF3P1JJ5D6DDpslGZ2L23N-0MtXC63I1m6x2Qa-E6-DYaDmC848EeIhOwBz4T2L6Pzp_IWWP5Dv4In-uvfHMg1lu4nvXQa0ORrdGXMBGjYwK9_HEspuvV9_IjT_s_kQLvOx8Hl6K9rHCevtaNKv_X-gWJHkw4</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Bozhinov, Angelina</creator><creator>Handzhiyski, Yordan</creator><creator>Genov, Krasimir</creator><creator>Daskalovska, Vera</creator><creator>Niwa, Toshimitsu</creator><creator>Ivan ov, Ivan</creator><creator>Mironova, Roumyana</creator><general>Elsevier Limited</general><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20120301</creationdate><title>Advanced glycation end products contribute to the immunogenicity of IFN-[beta] pharmaceuticals</title><author>Bozhinov, Angelina ; Handzhiyski, Yordan ; Genov, Krasimir ; Daskalovska, Vera ; Niwa, Toshimitsu ; Ivan ov, Ivan ; Mironova, Roumyana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_15048256893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Age</topic><topic>E coli</topic><topic>Multiple sclerosis</topic><topic>Patients</topic><topic>Pharmaceuticals</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bozhinov, Angelina</creatorcontrib><creatorcontrib>Handzhiyski, Yordan</creatorcontrib><creatorcontrib>Genov, Krasimir</creatorcontrib><creatorcontrib>Daskalovska, Vera</creatorcontrib><creatorcontrib>Niwa, Toshimitsu</creatorcontrib><creatorcontrib>Ivan ov, Ivan</creatorcontrib><creatorcontrib>Mironova, Roumyana</creatorcontrib><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bozhinov, Angelina</au><au>Handzhiyski, Yordan</au><au>Genov, Krasimir</au><au>Daskalovska, Vera</au><au>Niwa, Toshimitsu</au><au>Ivan ov, Ivan</au><au>Mironova, Roumyana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advanced glycation end products contribute to the immunogenicity of IFN-[beta] pharmaceuticals</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><date>2012-03-01</date><risdate>2012</risdate><volume>129</volume><issue>3</issue><spage>855</spage><pages>855-</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Protein-derived AGEs are formed in both eukaryotic and prokaryotic cells. [...]we hypothesized that human IFN-β produced in either Chinese hamster ovary cells (IFN-β1a) or E coli (IFN-β1b) will accumulate AGEs. [...]experimental data support involvement of both innate6 and adaptive7 immune reactions against AGEs.</abstract><cop>St. Louis</cop><pub>Elsevier Limited</pub><doi>10.1016/j.jaci.2011.10.035</doi></addata></record>
fulltext fulltext
identifier ISSN: 0091-6749
ispartof Journal of allergy and clinical immunology, 2012-03, Vol.129 (3), p.855
issn 0091-6749
1097-6825
language eng
recordid cdi_proquest_journals_1504825689
source Elsevier
subjects Age
E coli
Multiple sclerosis
Patients
Pharmaceuticals
Proteins
title Advanced glycation end products contribute to the immunogenicity of IFN-[beta] pharmaceuticals
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A30%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advanced%20glycation%20end%20products%20contribute%20to%20the%20immunogenicity%20of%20IFN-%5Bbeta%5D%20pharmaceuticals&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Bozhinov,%20Angelina&rft.date=2012-03-01&rft.volume=129&rft.issue=3&rft.spage=855&rft.pages=855-&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2011.10.035&rft_dat=%3Cproquest%3E3239424511%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_15048256893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1504825689&rft_id=info:pmid/&rfr_iscdi=true